SCM
NVO

Soleus Capital Management’s Novo Nordisk NVO Stock Holding History

Soleus Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-28,200
Closed -$1.41M – 86
2022
Q3 		$1.41M Buy
+28,200
New +$1.51M 0.19% 64

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Soleus Capital Management's NVO Position: Q4 2022 in Review

Soleus Capital Management sold out of Novo Nordisk (NVO) in Q4 2022, closing a stake of 28,200 shares — an estimated $1.41M sold.

Soleus Capital Management first reported a position in NVO in Q3 2022 and held it in 1 quarter. The position peaked at $1.41M in Q3 2022. 1,049 funds tracked by Wall St. Rank hold NVO as of Q4 2022.

  • Soleus Capital Management reported no remaining Novo Nordisk position as of Q4 2022 after selling out during the quarter.
  • Soleus Capital Management sold 28,200 Novo Nordisk shares in Q4 2022, an estimated $1.41M.
  • Soleus Capital Management first reported a position in Novo Nordisk in Q3 2022 and held it in 1 quarter.
  • Soleus Capital Management's Novo Nordisk position peaked at $1.41M in Q3 2022.
  • 1,049 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2022.

Based on Soleus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.